| RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer (NCT05313906) | Henan Cancer Hospital | 2022-05-07 |
| The Clinical Efficacy of Drug Sensitive Neoadjuvant Chemotherapy Based on Organoid Versus Traditional Neoadjuvant Chemotherapy in Advanced Gastric Cancer (NCT05351398) | Shanghai Minimally Invasive Surgery Center | 2022-04-01 |
| Study Evaluating Neoadjuvant Immunotherapy Increasing CD8+ Cell Infiltration in Advance Gastric Adenocarcinoma (NCT05270824) | Fujian Medical University | 2022-03-01 |
| IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 (NCT05805956) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2022-02-15 |
| Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients (NCT05221775) | Tianjin Medical University Cancer Institute and Hospital | 2021-11-01 |
| iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (NCT04808791) | AHS Cancer Control Alberta | 2021-10-27 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (NCT04491942) | National Cancer Institute (NCI) | 2021-08-25 |
| Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines (NCT04535401) | National Cancer Institute (NCI) | 2021-08-13 |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (NCT04704661) | National Cancer Institute (NCI) | 2021-08-09 |
| Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma (NCT04948125) | Henan Cancer Hospital | 2021-04-28 |
| A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma (NCT04718402) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-03-30 |
| Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) (NCT04739202) | Hospices Civils de Lyon | 2021-03-19 |
| Clinical Efficacy of Trastuzumab in Combination With Capecitabine and Oxaliplatin for the Treatment of HER2-positive Advanced Gastric Cancer. (NCT05997524) | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 2021-03-01 |
| Prospectively Predict the Immunotherapy Response of Gastric Cancer Based on Circulating Exosomal LncRNA-GC1 Biopsy (NCT05334849) | Lin Chen | 2018-11-01 |
| Prospective Study on Double-Stapling End-to-End Gastroduodenostomy Billroth-I Anastomosis in Laparoscopy-Assisted Surgery for Locally Advanced Distal Gastric Cancers (NCT05545293) | West China Hospital | 2017-09-14 |
| Study on Neoadjuvant Chemotherapy for Advanced Gastric Cancer (NCT02163291) | Peking University | 2013-12-01 |
| Phase III Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection (NCT01534546) | Peking University | 2012-03-01 |
| Dose Escalation Study of Liposomal Paclitaxel Plus Capecitabine in Chinese Patients With Advanced Gastric Carcinoma (NCT00881816) | Nanjing Sike Pharmaceutical Co., Ltd. | 2009-04-01 |
| A Study of Pemetrexed Plus Oxaliplatin as First Line Therapy in Advanced Gastric Carcinoma (NCT00192088) | Eli Lilly and Company | 2004-05-01 |